Respiratory Disease Vaccine Market 2025 to 2034
Respiratory Disease Vaccine Market 2025 to 2034
Respiratory Disease Vaccine Market (By Disease Type: Chronic Obstructive Pulmonary Disease (COPD), Pertussis, Pneumonia, Measles, Diphtheria; By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine; By Age Group: Pediatric, Adult; By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Others; By Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, Others; By Region: North America, Latin America, Europe, Asia-Pacific, Middle and East Africa) Industry Size, Share, Growth, Trends 2025 to 2034.
Customisation Request
Revenue, 2025
USD 101.10 Bn
Forecast Year, 2034
USD 121.36 Bn
CAGR, 2025 - 2034
2.05%
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The global respiratory disease vaccine market, valued at USD 101.1 billion in 2025, is projected to reach USD 121.36 billion by 2034, growing at a steady CAGR of 2.05%, driven by rising respiratory infections and expanding immunization initiatives worldwide.
Respiratory Disease Vaccine Market Size Analysis
Respiratory Disease Vaccine Market Size By Disease Type 2025 to 2034 (USD Billion)
| Disease Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Diphtheria | 10.47 | 10.69 | 10.91 | 11.13 | 11.36 | 11.59 | 11.83 | 12.07 | 12.32 | 12.57 |
| Measles | 15.48 | 15.80 | 16.12 | 16.45 | 16.79 | 17.13 | 17.49 | 17.84 | 18.21 | 18.58 |
| Pertussis | 17.03 | 17.38 | 17.73 | 18.09 | 18.47 | 18.84 | 19.23 | 19.62 | 20.03 | 20.44 |
| Chronic Obstructive Pulmonary Disease (COPD) | 27.62 | 28.18 | 28.76 | 29.35 | 29.95 | 30.56 | 31.19 | 31.83 | 32.48 | 33.15 |
| Pneumonia | 30.50 | 31.13 | 31.77 | 32.42 | 33.08 | 33.76 | 34.45 | 35.16 | 35.88 | 36.62 |
Respiratory Disease Vaccine Market Size By Type 2025 to 2034 (USD Billion)
| Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Combination Vaccine | 25.13 | 25.64 | 26.17 | 26.70 | 27.25 | 27.81 | 28.38 | 28.96 | 29.56 | 30.16 |
| Bacterial Vaccine | 34.56 | 35.27 | 35.99 | 36.73 | 37.48 | 38.25 | 39.04 | 39.84 | 40.65 | 41.49 |
| Viral Vaccine | 41.41 | 42.26 | 43.13 | 44.01 | 44.91 | 45.83 | 46.77 | 47.73 | 48.71 | 49.71 |
Respiratory Disease Vaccine Market Size By Age Group 2025 to 2034 (USD Billion)
| Age Group | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Pediatric | 45.00 | 45.93 | 46.87 | 47.83 | 48.81 | 49.81 | 50.83 | 51.87 | 52.94 | 54.02 |
| Adult | 56.10 | 57.25 | 58.42 | 59.62 | 60.84 | 62.09 | 63.36 | 64.66 | 65.99 | 67.34 |
Respiratory Disease Vaccine Market Size By Infection 2025 to 2034 (USD Billion)
| Infection | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Others | 12.56 | 12.81 | 13.08 | 13.34 | 13.62 | 13.90 | 14.18 | 14.47 | 14.77 | 15.07 |
| Respiratory Syncytial Virus (RSV) | 18.29 | 18.66 | 19.04 | 19.43 | 19.83 | 20.24 | 20.65 | 21.08 | 21.51 | 21.95 |
| Pneumonia | 20.62 | 21.05 | 21.48 | 21.92 | 22.37 | 22.82 | 23.29 | 23.77 | 24.26 | 24.75 |
| Influenza | 24.02 | 24.51 | 25.01 | 25.52 | 26.05 | 26.58 | 27.12 | 27.68 | 28.25 | 28.83 |
| COVID-19 | 25.62 | 26.15 | 26.68 | 27.23 | 27.79 | 28.36 | 28.94 | 29.53 | 30.14 | 30.75 |
Respiratory Disease Vaccine Market Size By Distribution Channel 2025 to 2034 (USD Billion)
| Distribution Channel | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Others | 15.82 | 16.15 | 16.48 | 16.82 | 17.16 | 17.51 | 17.87 | 18.24 | 18.61 | 19.00 |
| Government Suppliers | 27.65 | 28.22 | 28.80 | 29.39 | 29.99 | 30.61 | 31.23 | 31.87 | 32.53 | 33.19 |
| Hospital & Retail Pharmacies | 57.62 | 58.80 | 60.01 | 61.24 | 62.49 | 63.78 | 65.08 | 66.42 | 67.78 | 69.17 |
Respiratory Disease Vaccine Market Size By Region 2025 to 2034 (USD Billion)
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Middle East and Africa | 6.32 | 6.45 | 6.58 | 6.72 | 6.86 | 7.00 | 7.14 | 7.29 | 7.44 | 7.59 |
| Latin America | 8.31 | 8.48 | 8.65 | 8.83 | 9.01 | 9.19 | 9.38 | 9.57 | 9.77 | 9.97 |
| Asia Pacific | 24.55 | 25.05 | 25.57 | 26.09 | 26.63 | 27.17 | 27.73 | 28.30 | 28.88 | 29.47 |
| Europe | 26.20 | 26.74 | 27.28 | 27.84 | 28.41 | 29.00 | 29.59 | 30.20 | 30.82 | 31.45 |
| North America | 35.72 | 36.45 | 37.20 | 37.96 | 38.74 | 39.54 | 40.35 | 41.17 | 42.02 | 42.88 |
Respiratory Disease Vaccine Market Size to Reach USD 121.36 Billion by 2034
The global respiratory disease vaccine market size was evaluated at USD 101.1 billion in 2025 and is expected to grow around USD 121.36 billion by 2034 a CAGR of 2.05%.
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
